Founder & Chief Executive Officer
Over his 30-year career, Bruno has helped launch and scale some of the world’s most innovative telecommunication products, mobile phones and sensors. Before co-founding BOYDSense, Bruno was the Chief Technology Officer at Sensitive Object. He also served as Vice President of R&D at Siemens Mobile Phones, and studied at the Conservatoire National des Arts et Metiers.
Sandrine Isz, PhD
Chief Science Officer
With an extensive academic background and 25 years of career research, Sandrine has domain expertise in sensors, nanomaterials, materials chemistry, analytical chemistry, human breath analysis, data mining and artificial intelligence. Her previous experience includes serving as Technical Lead at Merck Prolabo, and completing her post-doctoral studies at Israel’s Weizmann Institute.
Chief Financial Officer
Arnaud has experience as a founding CEO of both newly-formed organizations and established companies growing at a rapid pace. He is an expert in the financial challenges faced by companies in high-growth sectors, and is skilled in working in multinational environments, particularly in the telecommunications, Internet and software industries. He has a degree in civil engineering the Ecole Nationale Supérieure des Mines de Saint-Etienne, as well as an MBA from ESSEC Business School in Paris, France.
Sébastien PELLETIER, MS
Team System Manager
Cross functional and multi-site team’s management, deployment of product development process with ISO 9001:2015 certification. Embedded Systems Engineer at Sensitive Object (acquired by TE Connectivity)
Thomas MONROUSSEAU, PhD
R&D Eng, Data Scientist
Development of tools to treat data extracted from Lassie prototype, classification of predictive algorithms and mobile application development.
Guillaume JUNCA, MS
Development of mathematical models and algorithms allowing Lassie to provide useful information to users
Julien BOYE, MS
Lassie mechanical design, implementation of test benches and test protocols, testing, data treatment and reporting
Non Executive Chairman
Anton Kitterlberger and his team built mySugr - a digital service focused on people with diabetes, that has been acquired by Roche in 2017 and is now serving over 2 million users and employs a team of over 170. Through the open service platform, he is well connected through the diabetes and cardiovascular space and is an active startup advisor and Investor.
Supervisory Board Independent Member
Over his 20-year career, Ben has worked in different leading marketing and sales position, primarily in diabetes devices and consumer business at LifeScan, Johnson & Johnson, Bayer and Sanofi. Ben has launched more than 10 diabetes devices and software as a medical device in more than 25 countries world wide, e.g. OneTouch products, MyStar products and My DoseCoach. He was the commercial lead to implement and execute the new diabetes category of algorithm based drug dosing advisors.
JOLT CAPITAL partner since 2015 and currently a board member of Eyeota and Alpha MOS (ENXTPA: ALM). He has experience across large corporations and dynamic start-ups. His experience as a senior manager includes serving as VP Business Development with Orange, Country Manager for France with both NEC and Nokia, and also as Global Business Unit Manager with Nokia. Laurent has also held executive positions with smaller technology companies (DxO Labs, Coronis Systems, Varioptic) where he experienced all stages from growth to exit including, equity raising, technology development, commercial expansion and trade sale. Laurent’s business experience centres on IT (networks, mobiles, software, chips & components) and Clean Tech (renewables, smart grid, energy efficiency). He graduated from Telecom Paris Tech and won the French Digital Technology Manager award in 1998
Before joining AMBROSIA Investments, Adrien Tardy started his career at Louis Dreyfus Company (“LDC”) in 2000 Between 2000 and 2005, he worked in various capacities related to business and corporate development in the telecom industry at LDCom/Neuf Cegetel. In 2005, began working in the Office of the CEO of the Louis Dreyfus Group, later being appointed as Global Head of Mergers and Acquisitions and subsequently Head of Group Corporate Finance & Strategy of LDC. He then became Global Head of Strategy and Corporate Finance for Louis Dreyfus Company and then Chief Financial Officer for the Europe and Black Sea region. Adrien Tardy was also Vice Chairman of the Board of Directors of Biosev SA (a listed Brazilian subsidiary of LDC and active in the production and processing of cane sugar). He graduated from the French business school ESSEC.
Pierre Sbabo has 25 years of experience in process applications for the Food & Beverage industry, as well as the pharmaceutical and oil & gas segments. Throughout his career, he held commercial then general management roles in Europe, Asia and the United States for global corporations like General Electric Water & Process Technologies, Pentair Filtration and Separation, NSF and most recently SPX Flow, where he was in charge of the EMEA Food & Beverage and Industrial segments ($600M). Pierre lived for 15 years in Asia (China, Thailand, Singapore), the United States and various European countries. He is now based at the headquarters of Alpha-MOS in Toulouse, France. Pierre holds a Master degree in Marketing and International Business from Ecole Supérieure de Commerce de Chambéry, France.
Medical Advisory Board
Guido Freckmann, MD
Dr Freckmann is Medical Director and General Manager of the “Institut für Diabetes-Technologie Forschungs” (IDT), Germany, independent research organization specialized in diabetes technology.
Diabetologist of the German Diabetes Association, he was principal investigator for different studies, about CGM systems and other developments and cooperates with several industrial and non-industrial partners.
Steven Chen, MD
Dr. Chen is an endocrinologist physician with a broad, diverse background including obesity, diabetes and academic clinical research, clinical practice, pharmaceutical clinical development (phase 1-4) and medical affairs. He also has US and global R&D experience with a special focus on China within emerging markets.
Timothy Garvey, MD
Dr. Garvey is Professor of Medicine in the Department of Nutrition Sciences at the University of Alabama. Passionate about healthcare, he has achieved international recognition for his research in the metabolic, molecular and genetic pathogenesis of insulin resistance, Type 2 diabetes and obesity. He graduated cum laude from the Saint Louis University School of Medicine.
William Polonsky, PhD
A globally recognized leader in behavioral health focusing on obesity and diabetes, William is the associate Clinical Professor in Psychiatry at the University of California San Diego. He is an active researcher in the field of behavioral diabetes, and has served on the editorial boards of Diabetes Care, Diabetes Forecast, Clinical Diabetes, Diabetes Self-Management and Diabetes Health.
An Alpha MOS company, the leader in volatile organic compound analysis.
Our parent company is Alpha MOS, a global provider of gas-compound sensing equipment with over two decades of experience around the world. The team at Alpha MOS includes 25 engineers and scientists. Our diverse backgrounds include biochemistry, biophysics, analytical chemistry, chemical sensors, gas sensing analytics, statistics, mathematics, electronics, and software. www.alpha-mos.com